"Designing Growth Strategies is in our DNA"
The global alpha-1 antitrypsin deficiency treatment market size expected to drive significant growth by 2026. Alpha-1 antitrypsin is one of the protein synthesised in the liver and travels through the blood protecting the organs of the body from the harmful effects of other proteins. Alpha-1 Antitrypsin Deficiency (AATA), also called genetic Chronic Obstructive Pulmonary Disease (COPD), refers to a genetic condition resulting in increased susceptibility for lung and related disease.
Every individual receives two copies of alpha-1 antitrypsin genes, one form each parent. Individuals that receive one normal and one damaged or two damaged copies of alpha-1 antitrypsin genes have considered to have alpha-1 antitrypsin deficiency. The treatment of alpha-1 antitrypsin deficiency has received huge attention due to the guidelines and recommendations given by the government of different countries. In 2016, the FDA granted expanded label approval to Glassia a drug for alpha-1 antitrypsin deficiency by Kamada Ltd., for self-infusion, enabling patients to self-administer the drug. This is expected to increase the demand for Glassia further augmenting the global alpha-1 antitrypsin deficiency treatment market.
The growth in global alpha 1 antitrypsin deficiency treatment market size is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.
To gain extensive insights into the market, Request for Customization
However, lack of diagnostic methods due to which alpha-1 antitrypsin deficiency remains undetected or sometimes misinterpreted as asthma is a major factor that can hamper the growth in alpha-1 antitrypsin deficiency treatment market. According to the Alpha-1 Foundation, the around 3% of all the people with Chronic Obstructive Pulmonary Disease (COPD) are likely to have undetected alpha-1 antitrypsin deficiency, which can act as a restraining factor in the growth in global alpha-1 antitrypsin deficiency treatment market.
Some of the major companies that are present in the global alpha 1 antitrypsin deficiency treatment market are Grifols S.A., CSL Limited, Baxter, Kamada Ltd., Takeda Pharmaceutical Company Limited, Abeona Therapeutics Inc., and other players.
By Drug Class
By Route of Administration
By Distribution Channel
The alpha-1 proteinase inhibitor segment is estimated to witness a fast expansion which can be attributed to the new product launch, potential pipeline candidates and increased research on existing products. In August 2015, European Commission granted marketing authorization to Respreeza, a drug for the treatment of alpha-1 antitrypsin deficiency manufactured by CSL Behring in all European union, which is expected to drive the alpha-1 proteinase inhibitor segment.
The global alpha-1 proteinase inhibitor market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In North America, the alpha-1 antitrypsin deficiency treatment market is expected to grow during the projected period owing to the recommendations for augmentation therapy for alpha-1 antitrypsin deficiency treatment. The Clinical Practice Guidelines published in the Journal of the COPD Foundation recommends augmentation therapy for all those who have alpha-associated lung diseases. The alpha-1 antitrypsin deficiency treatment market in Europe and Asia Pacific is anticipated to expand in the forecast period owing to the rising prevalence of alpha-1 antitrypsin deficiency.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry